Hey Green - I was also irritated about the delay, particularly when it looked like that the trial would be fully enrolled by mid-year. but it looks like that they increased the enrolment to 171 patients from the original 154 targeted. the announcement is good in that they allocated 33 patients with PD-L1 less than 1 to cohort B.
What is annoying is why didn't IMM tell shareholders that. A further expansion of the trial is obviously a good thing, with more data to help support approval (Marc has previously said that if the data is compelling IMM will go to the FDA to seek approval based on these results).
Ann: Immutep Completes Enrolment for TACTI-003 Phase IIb Trial, page-5
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
45.5¢ |
Change
0.020(4.60%) |
Mkt cap ! $540.9M | |||
| Open | High | Low | Value | Volume |
| 44.0¢ | 45.5¢ | 43.0¢ | $439.6K | 992.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 10000 | 45.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 45.5¢ | 65958 | 3 |
View Market Depth
| Last trade - 16.10pm 17/05/2024 (20 minute delay) ? |
|
|||||
|
Last
44.8¢ |
Change
0.020 ( 3.21 %) |
||||
| Open | High | Low | Volume | ||
| 44.0¢ | 45.0¢ | 43.0¢ | 240557 | ||
| Last updated 15.59pm 17/05/2024 ? | |||||
| IMM (ASX) Chart |